Medpace Holdings Inc (MEDP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medpace Holdings Inc (MEDP) has a cash flow conversion efficiency ratio of 0.373x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($162.01 Million) by net assets ($433.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MEDP stock market capitalisation for the company's overall valuation and market capitalisation.
Medpace Holdings Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Medpace Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medpace Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medpace Holdings Inc ranked by their cash flow conversion efficiency. Explore how high is Medpace Holdings Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Toast Inc
NYSE:TOST
|
0.070x |
|
News Corporation
AU:NWSLV
|
0.055x |
|
Banco Santander Chile
NYSE:BSAC
|
-0.042x |
|
Computershare Ltd
AU:CPU
|
0.153x |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
0.028x |
|
Cholamandalam Investment and Finance Company Limited
NSE:CHOLAFIN
|
-1.249x |
|
Ast Spacemobile Inc
NASDAQ:ASTS
|
-0.040x |
|
WESCO International Inc
NYSE:WCC
|
0.010x |
Annual Cash Flow Conversion Efficiency for Medpace Holdings Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Medpace Holdings Inc from 2014 to 2025. View Medpace Holdings Inc (MEDP) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $459.07 Million | $713.22 Million | 1.554x | +110.67% |
| 2024-12-31 | $825.54 Million | $608.82 Million | 0.737x | -4.88% |
| 2023-12-31 | $558.95 Million | $433.37 Million | 0.775x | -22.80% |
| 2022-12-31 | $386.39 Million | $388.05 Million | 1.004x | +263.44% |
| 2021-12-31 | $952.93 Million | $263.33 Million | 0.276x | -13.92% |
| 2020-12-31 | $805.78 Million | $258.68 Million | 0.321x | +15.50% |
| 2019-12-31 | $726.28 Million | $201.87 Million | 0.278x | +4.68% |
| 2018-12-31 | $589.70 Million | $156.58 Million | 0.266x | +37.29% |
| 2017-12-31 | $503.53 Million | $97.39 Million | 0.193x | +28.76% |
| 2016-12-31 | $610.71 Million | $91.73 Million | 0.150x | -27.67% |
| 2015-12-31 | $413.47 Million | $85.87 Million | 0.208x | +11.01% |
| 2014-12-31 | $401.97 Million | $75.20 Million | 0.187x | -- |
About Medpace Holdings Inc
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medica… Read more